Stock Price
138.23
Daily Change
-0.75 -0.54%
Monthly
1.65%
Yearly
-8.58%
Q1 Forecast
131.87

Neurocrine Biosciences reported $2.17 in EPS Earnings Per Share for its fiscal quarter ending in September of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q4 Dec/2025 1.86 1.69 Feb/11 2026
FY2025Q3 Sep/2025 2.17 1.56 1.81 Oct/28 2025
FY2025Q2 Jun/2025 1.65 0.98 1.63 Jul/30 2025
FY2025Q1 Mar/2025 0.70 0.86 1.20 May/05 2025
FY2024Q4 Dec/2024 1.69 1.57 1.54 Feb/06 2025




Eps Change Date
AbbVie USD 2.71 0.85 Dec/2025
Acadia Pharmaceuticals USD 0.42 0.26 Sep/2025
Agios Pharmaceuticals USD -1.78 0.15 Sep/2025
ALKERMES USD 0.49 0.03 Sep/2025
Alnylam Pharmaceuticals USD 2.9 2.58 Sep/2025
Amgen USD 5.29 0.35 Dec/2025
Biogen USD 4.81 0.66 Sep/2025
BioMarin Pharmaceutical USD 0.12 1.32 Sep/2025
Cytokinetics USD -2.55 1.43 Sep/2025
Dynavax Technologies USD 0.21 0.07 Sep/2025
Exelixis USD 0.78 0.03 Sep/2025
Gilead Sciences USD 2.47 0.46 Sep/2025
Halozyme Therapeutics USD 1.72 0.18 Sep/2025
Incyte USD 2.26 0.69 Sep/2025
Ionis Pharmaceuticals USD -0.8 1.5 Sep/2025
Neurocrine Biosciences USD 2.17 0.52 Sep/2025
Pfizer USD 0.66 0.21 Dec/2025
Prothena USD -0.68 1.66 Sep/2025
Regeneron Pharmaceuticals USD 11.44 0.39 Dec/2025
Repligen USD 0.46 0.09 Sep/2025
Sarepta Therapeutics USD -0.13 2.15 Sep/2025
Teva Pharmaceutical Industries USD 2.98 0.43 Dec/2025
Ultragenyx Pharmaceutical USD -1.81 0.64 Sep/2025
Vertex Pharmaceuticals USD 4.8 0.28 Sep/2025